Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
BeiGene Australia Pty Ltd
This is a randomised trial with three arms. In Arm A (Experimental), participants will receive tislelizumab 200 milligrams (mg) intravenously followed by ociperlimab 900 mg intravenously once every 3 weeks. In Arm B (Active comparator), Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks. In Arm C (Placebo comparator), Participants will receive tislelizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.